🔗 Share this article

A shadow economy for unlicensed weight-loss medications is being driven by social media fitness personalities and sellers on messaging platforms, based on new investigations.

Investigational Treatment Gaining Traction Via Social Media

The experimental drug, which is still in research studies, is being advertised by social media influencers for its alleged weight-reducing effects. Followers are encouraged to message these accounts directly for source information, while also obtaining discount codes.

Active Commerce on Social Networks

Additionally, a flourishing market exists on messaging services, where communities with thousands of members share “before and after” images, injection guides and claims of rapid UK delivery. Vendors market the drug there before redirecting customers to WhatsApp for purchases.

Understanding The Experimental Drug

This medication is an investigational injectable developed by American pharmaceutical company Eli Lilly. The treatment targets three gut hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Preliminary studies suggest it could help patients reduce up to 25% of their total weight. Referred to as the “triple G”, the substance is being promoted online as the next Ozempic.

Healthcare Professionals Voice Concerns

However, physicians and pharmacists have warned that the distribution of what is still an unapproved drug in the UK is a cause for concern and could lead to individuals administering substances of unknown origin.

Some experts stated the popularity for the experimental drug could be connected to the increasing cost of licensed slimming products such as Mounjaro.

Legal Status and Implementation

Marketing retatrutide on social media or messaging apps is prohibited in the UK, as it is an unapproved drug that cannot be marketed or distributed for human use under the British medical regulations.

Some influencers try to sidestep the rules by referring to the substance as a “research chemical” or citing it as “not for human consumption”. The substance is not a controlled drug, but advertising and supply can still violate medicines, advertising, and consumer regulations, potentially leading to fines, prosecution or prison.

Platform Reaction and Content Elimination

According to TikTok, the platform has taken down violative material and prohibited associated hashtags and search suggestions. The company said it was committed to maintaining the service secure and investing in enhancing compliance measures.

Digital Trading Activities

Investigations also discovered groups with up to nine thousand members marketing retatrutide using Telegram's built-in search feature, which functions like a public directory. Entering “retatrutide” immediately brings up groups with thousands of members, populated with photos of weight loss, positive testimonials and step-by-step instructions for mixing or administering at residence.

After moments of joining one group, a vendor shared contact information, where the majority of purchases take place. The seller provided an instruction manual and promised delivery within two days. When questioned whether the product was genuine, one seller said: “You can’t be sure.” Another provided a image of a alleged laboratory certificate. None inquired about weight, medical conditions or past usage.

Product Details and Costs

Inside these groups, posts show dark colored packages with postal service labels, claiming to contain new batches. One message read: “It took eight of us to load them this morning.”

Buyers can select between powder vials, prepared at residence with sterile water, or ready-to-use injectors usually sold at 160 pounds for 20mg. When questioned how long a injector should last, vendors give conflicting responses ranging from a several days to “depends on your body”.

Service Oversight and Security Measures

A spokesperson for the messaging service said it regularly monitored dangerous content on its platform including material that promoted the “misuse of controlled medications”. The organization added that it removed “millions of pieces of harmful content each day”.

Healthcare Expert Warnings

“People are administering materials they can’t verify. Even if the research behind retatrutide is sound, these digital versions may not include what they advertise,” stated Jason Murphy, the director of pharmacy at a pharmacy service.

Dr Crystal Wyllie of Asda Online Doctor linked the surge in demand to current price rises for authorized slimming medications such as Mounjaro. “With costs increasing, individuals are turning to social media. But counterfeit injections are extremely risky. You cannot know what’s contained or whether the conditions they were made in was sterile,” she explained.

Her team has already encountered patients harmed by self-injection from unverified sources. “We recognize the disappointment, but purchasing from messaging apps or communication platforms is gambling with your health,” said Wyllie. “These materials could be impure or incorrectly dosed.”

Manufacturer Statement

A representative from Eli Lilly stated the substance was in phase 3 research studies and had not been reviewed or authorized by any government authority anywhere in the world. “Consequently at this point no one can market [it] for personal consumption,” they said, adding that any item “falsely representing itself as a company investigational product not yet authorized … may expose users to potentially serious medical dangers”.